| scholarly article | Q13442814 |
| P50 | author | Amy Taylor | Q56460940 |
| Marc Tischkowitz | Q66439010 | ||
| Clare Turnbull | Q67482869 | ||
| P2093 | author name string | Lucy Side | |
| Ian M Frayling | |||
| Angela F Brady | |||
| Helen Hanson | |||
| UK Cancer Genetics Group (UK-CGG) | |||
| P2860 | cites work | Multigene testing of moderate-risk genes: be mindful of the missense | Q24658557 |
| Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers | Q30652890 | ||
| Counselling framework for moderate-penetrance cancer-susceptibility mutations | Q33911135 | ||
| Rare variants in the ATM gene and risk of breast cancer | Q35608690 | ||
| Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
| Gene-panel sequencing and the prediction of breast-cancer risk | Q36175072 | ||
| Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer | Q36276527 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts | Q36824964 | ||
| Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families | Q37025837 | ||
| No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing | Q37079859 | ||
| Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model | Q37378034 | ||
| Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing | Q37710155 | ||
| Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). | Q37739029 | ||
| Peutz-Jeghers syndrome: a systematic review and recommendations for management | Q37767967 | ||
| EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients | Q38069531 | ||
| Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment | Q38808384 | ||
| Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review | Q38974107 | ||
| NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. | Q39045746 | ||
| Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database | Q40103447 | ||
| Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database | Q40221041 | ||
| Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
| Guidelines for the clinical management of familial adenomatous polyposis (FAP). | Q54428028 | ||
| TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes | Q58006192 | ||
| CDH1 germline mutations: different syndromes, same management? | Q87872784 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1-6 | |
| 372-377 | |||
| P577 | publication date | 2018-04-16 | |
| P1433 | published in | Journal of Medical Genetics | Q14640281 |
| P1476 | title | Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. | |
| P478 | volume | 55 |
| Q92377257 | BARD1 is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation |
| Q90241672 | Breast cancer |
| Q90036958 | Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels |
| Q89855469 | Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer |
| Q99243158 | Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients |
| Q92268185 | Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer |
| Q59809084 | Gene panel testing for breast cancer should not be used to confirm syndromic gene associations |
| Q89659606 | Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? |
| Q95326700 | Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction |
| Q90261353 | Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study |
| Q91767864 | Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing |
| Q91241924 | Strategies for Improving Access to Hereditary Cancer Testing: Recommendations from Stakeholders |
Search more.